Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Theseus Pharmaceuticals (NASDAQ: THRX) announced significant 2021 developments, including the initiation of a Phase 1/2 trial for lead candidate THE-630 targeting advanced GIST patients. The company added cash reserves of $244.7 million as of December 31, 2021, expected to fund operations into 2024. However, net losses increased to $8.7 million for Q4 2021 and $27.3 million for the full year, reflecting R&D and administrative expenses rising to $18.3 million and $9.0 million, respectively. Despite these losses, the company remains focused on advancing its clinical pipeline.
- Initiated Phase 1/2 clinical trial for THE-630 in advanced GIST patients.
- Successful IPO raised $178.8 million.
- Strong cash position of $244.7 million to support operations into 2024.
- Net loss increased to $8.7 million for Q4 2021 and $27.3 million for the full year.
- R&D expenses rose to $18.3 million in 2021, up from $6.0 million in 2020.
- G&A expenses surged to $9.0 million in 2021 from $0.9 million in 2020.
CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2021.
"2021 was a transformative year for Theseus—we evolved into a clinical stage company, strengthened our team, and completed a successful IPO," said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. "In January 2022 we initiated a Phase 1/2 clinical trial to evaluate our lead candidate, THE-630, in patients with advanced GIST and continue to drive towards development candidate nomination for our fourth-generation EGFR program in non-small cell lung cancer. Over the course of this year, we look forward to executing across our pipeline, which includes advancing THE-630 in the clinic, initiating IND-enabling studies of our second development candidate targeting EGFR, and expanding our pipeline with one or more additional kinase targets."
Recent Business Highlights and Anticipated Milestones:
- Initiated Phase 1/2 clinical trial to evaluate THE-630 in patients with GIST. First patient treated in January 2022 in a Phase 1/2 dose escalation and expansion clinical trial of THE-630 in patients with advanced GIST. THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy. Initial data from the Phase 1 portion of the clinical trial is expected to be presented at a scientific meeting in the first half of 2023.
- Nomination of development candidate for fourth-generation EGFR program expected in the third quarter of 2022. Theseus expects to nominate an EGFR candidate designed to inhibit the full range of single-, double-, and triple-mutant EGFR variants found in the tumors of patients with EGFR-mutant NSCLC that have developed resistance to osimertinib, including the C797S mutation. Preclinical data is expected to be presented at the American Association for Cancer Research (AACR) Annual Meeting in April and at a scientific conference in the second half of 2022. IND submission is expected in 2023.
- One or more additional kinase targets expected to be nominated by the end of 2022.
- Successfully completed initial public offering (IPO). In October 2021, the Company completed a successful IPO, raising
$178.8 million in aggregate gross proceeds, and listed on the Nasdaq Global Select Market.
Fourth Quarter and Full Year Financial Results:
- Cash Position: As of December 31, 2021, Theseus had cash and cash equivalents of
$244.7 million . Theseus expects its cash and cash equivalents, including proceeds from the IPO, to fund operations and capital expenditures into the second half of 2024 based on its current operating plan. - R&D Expenses: Research and development expenses were
$5.0 million for the fourth quarter of 2021, as compared to$2.5 million for the fourth quarter of 2020. This increase was primarily due to$1.6 million of increased employee-related costs, and$0.9 million in increased expenses for clinical and preclinical studies. Research and development expenses were$18.3 million for the full year 2021, as compared to$6.0 million for the full year 2020. - G&A Expenses: General and administrative expenses were
$3.6 million for the fourth quarter of 2021, as compared to$0.4 million for the fourth quarter of 2020. This increase was primarily due to$1.6 million of increased employee-related costs, primarily due to increases in our headcount, as well as$1.7 million of increased general expenses, primarily driven by public company-related costs. General and administrative expenses were$9.0 million for the full year 2021, as compared to$0.9 million for the full year 2020. - Net Loss: Net loss was
$8.7 million for the fourth quarter of 2021, as compared to a net loss of$2.9 million for the fourth quarter of 2020. Net loss was$27.3 million for the full year 2021, or a net loss per share of$2.84 , as compared to a net loss of$12.0 million for the full year 2020, or a net loss per share of$21.10 .
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.
Cautionary Statement Regarding Forward Looking Statements
Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Theseus' strategy, future operations, prospects and plans, the structure and timing of its planned preclinical studies and clinical trials, expected milestones, market opportunity and sizing and objectives of management, including in relation to the Phase 1/2 dose escalation and expansion clinical trial for THE-630, EGFR inhibitor program and other programs.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, such as those described from time to time in the reports Theseus files with the Securities and Exchange Commission (SEC), including Theseus' Form 10-Q for the quarter ended September 30, 2021 filed with the SEC on November 15, 2021 and Theseus' Form 10-K for the year ended December 31, 2021 expected to be filed with the SEC in the first quarter of 2022. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Theseus' management team and speak only as of the date hereof, and Theseus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Theseus Pharmaceuticals, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||
(in thousands, except share and per share data) | ||||||||||||
Three Months Ended December 31, | Year Ended December 31, | |||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 5,022 | $ | 2,488 | $ | 18,328 | $ | 5,958 | ||||
General and administrative | 3,637 | 400 | 9,008 | 878 | ||||||||
Total operating expenses | 8,659 | 2,888 | 27,336 | 6,836 | ||||||||
Loss from operations | (8,659) | (2,888) | (27,336) | (6,836) | ||||||||
Other income (expense), net | 3 | (2) | 28 | (5,161) | ||||||||
Net loss | $ | (8,656) | $ | (2,890) | $ | (27,308) | $ | (11,997) | ||||
Net loss per share attributable to common | $ | (0.24) | $ | (3.78) | $ | (2.84) | $ | (21.10) | ||||
Weighted-average common stock outstanding—basic | 35,877,802 | 763,746 | 9,631,818 | 568,467 | ||||||||
Theseus Pharmaceuticals, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(in thousands) | ||||||
December 31, | ||||||
2021 | 2020 | |||||
Assets | ||||||
Cash and cash equivalents | $ | 244,662 | $ | 8,457 | ||
Other assets | 6,267 | 157 | ||||
Total assets | 250,929 | 8,614 | ||||
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||||||
Liabilities | 4,495 | 1,595 | ||||
Redeemable convertible preferred stock | - | 41,289 | ||||
Stockholders' equity (deficit) | 246,434 | (34,270) | ||||
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $ | 250,929 | $ | 8,614 | ||
View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-announces-business-highlights-and-reports-fourth-quarter-and-full-year-2021-financial-results-301499774.html
SOURCE Theseus Pharmaceuticals
FAQ
What are the latest financial results for Theseus Pharmaceuticals (THRX)?
What is the status of Theseus Pharmaceuticals' lead candidate THE-630?
How much cash does Theseus Pharmaceuticals have as of December 31, 2021?
What milestones is Theseus Pharmaceuticals anticipating in 2022?
